Shield Therapeutics (STX) Q2 2026 TU earnings summary

Executive summary

• ACCRUFeR (Feraccru in Europe) is the sole product, targeting iron deficiency anemia, with strong IP protection through the mid-2030s and estimated peak revenues of $450 million.

• Q2 2026 net revenues reached $11.9M, with H1 2026 revenues at $30.4M, up 41% year-over-year, reflecting strong commercial segment performance and a $7.9M milestone from China.

• ACCRUFERⓇ remains the #1 branded prescription oral iron in the US, with expanded pediatric indications in the US, UK, and EU.

• U.S. is the only direct sales market; commercial segment now prioritized after Medicaid restrictions in New York impacted Q2 results.

• Michael Jensen appointed CFO, bringing over 20 years of financial leadership experience in healthcare sectors, effective September 1st.

Financial highlights

• H1 2026 total revenues increased to $30.4M, driven by a $7.9M milestone payment from ASK in China and higher partner royalties.

• Q2 2026 net revenue was $11.9M, down from $14.3M in Q2 2025, with US net revenues at $10.3M and an average net price of $208.

• ACCRUFeR net revenues for H1 were $20.1M, up 5% year-over-year, with 102,000 prescriptions at a $199 net price.

• EBIT profitability achieved in H1; cash and equivalents at $8.3M as of June 30, down from $12.4M in Q1.

Outlook and guidance

• Focus remains on growing ACCRUFeR revenues, achieving full-year profitability, and diversifying revenue streams.

• Management expresses confidence in pivoting commercial strategy away from Medicaid to focus on commercial business.

• Peak sales targets for ACCRUFeR remain realistic, with market share currently at 4-5% and significant room for growth.